Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001172661-25-001230
Filing Date
2025-02-14
Accepted
2025-02-14 16:56:39
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 8928
  Complete submission text file 0001172661-25-001230.txt   10648
Mailing Address 510 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10022
Business Address 510 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10022 (212) 231-4932
ARMISTICE CAPITAL, LLC (Filed by) CIK: 0001601086 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (800) 466-6059
Aligos Therapeutics, Inc. (Subject) CIK: 0001799448 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91770 | Film No.: 25630416
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)